血清皮质醇、胰岛素生长因子结合蛋白-3、25-羟维生素D在特发性矮小症患儿中的表达及意义

doi:10.11852/zgetbjzz2023-0716

摘要/Abstract

摘要： 目的探讨血清皮质醇、胰岛素生长因子结合蛋白-3(IGFBP-3)、25-羟维生素D[25-(OH)D]在特发性矮小症(ISS)患儿中的表达及意义。方法选取2020年4月—2022年6月于成都市龙泉驿区妇幼保健院诊治的86例ISS患儿作为观察组,同期选取43例健康体检儿童为对照组,对比基线资料、血清皮质醇、IGFBP-3、25-(OH)D水平;采用Pearson法分析皮质醇、IGFBP-3、25-(OH)D与身高、体重、体质量指数(BMI)的相关性;采用Logistic回归模型构建皮质醇、IGFBP-3、25-(OH)D联合诊断ISS模型;采用ROC曲线模型分析皮质醇、IGFBP-3、25-(OH)D及三项联合诊断ISS的AUC值、敏感度、特异度。结果观察组身高、体重、BMI均低于对照组(t=6.472、15.193、5.208,P＜0.05)。观察组皮质醇水平高于对照组,而IGFBP-3、25-(OH)D水平低于对照组(t=4.505、5.341、4.857,P＜0.05)。Pearson相关性分析显示,血清皮质醇水平与身高、体重、BMI呈负相关(r＝-0.231、-0.716、-0.720,P＜0.05);血清IGFBP-3、25-(OH)D水平分别与身高、体重、BMI呈正相关(r=0.200、0.612、0.636、0.365、0.716、0.715,P＜0.05)。ROC曲线分析显示,皮质醇、IGFBP-3、25-(OH)D及三项联合诊断ISS的AUC值分别为0.750、0.736、0.728、0.941(P＜0.05),敏感度分别为54.70%、93.00%、90.70%、93.00%;特异度分别为88.40%、53.50%、51.20%、79.10%。结论血清皮质醇、IGFBP-3、25-(OH)D在ISS患儿中呈异常表达,监测其水平变化有利于及早发现ISS提供指导。

关键词: 皮质醇, 胰岛素生长因子结合蛋白-3, 25-羟维生素D, 特发性矮小症

Abstract: Objective To explore the expression and significance of serum cortisol, insulin growth factor binding protein-3(IGFBP-3), and 25-hydroxyvitamin D [25-(OH)D] in children with idiopathic short stature(ISS). Methods A total of 86 patients with ISS diagnosed and treated in Longquanyi District Maternal and Child Health Hospital of Chengdu from April 2020 to June 2022 were selected as the study subjects. Meabwhile, 43 children who took physical examination were enrolled into control group. Baseline data, serum cortisol, IGFBP-3, 25-(OH)D levels were compared. Pearson analysis was used to test the associations of cortisol, IGFBP-3, and 25-(OH)D with height, weight and body mass index(BMI). Logistic regression model was used to construct a combination model of cortisol, IGFBP-3 and 25-(OH)D for diagnosing ISS. The AUC value, sensitivity, and specificity of cortisol, IGFBP-3, 25-(OH)D and three combined indicators for diagnozing ISS were analyzed using the ROC curve model. Results Height, weight and BMI of the observation group were significantly lower than those of the control group(t=6.472, 15.193, 5.208, P<0.05). Serum level of cortisol in the observation group was significantly higher than that in the control group, while IGFBP-3 and 25-(OH)D levles were significantly lower than those in the control group(t=4.505, 5.341, 4.857, P<0.05). Pearson correlation analysis showed that serumcortisol level was negatively correlated with height, body weight and BMI(r＝-0.231,-0.716,-0.720, P<0.05), while serum IGFBP-3 and 25-(OH)D levels were positively correlated with height, body weight and BMI(r=0.200, 0.612, 0.636, 0.365, 0.716, 0.715, P<0.05). ROC curve analysis showed that the AUC values of cortisol, IGFBP-3, 25-(OH)D and three combined diagnosis of ISS were 0.750, 0.736, 0.728, 0.941(P<0.05), and the sensitivities were 54.70%, 93.00%, 90.70% and 93.00%, respectively, while the specificity was 88.40%, 53.50%, 51.20% and 79.10%, respectively. Conclusions Serum cortisol, IGFBP-3, 25-(OH) D levels show an abnormal expression trend in children with ISS. Monitoring the changes in their levels is beneficial to provide guidance for the early detection of ISS.

Key words: cortisol, insulin growth factor binding protein-3, 25-hydroxyvitamin D, idiopathic short stature

中图分类号:

R725.8

贺莉, 吕加利, 李俊, 杜春华. 血清皮质醇、胰岛素生长因子结合蛋白-3、25-羟维生素D在特发性矮小症患儿中的表达及意义[J]. 中国儿童保健杂志, 2024, 32(6): 678-681.

HE Li, LYU Jiali, LI Jun, DU Chunhua. Expression and significance of serum cortisol, insulin growth factor-binding protein-3, 25-hydroxyvitamin D in children with idiopathic short stature[J]. Chinese Journal of Child Health Care, 2024, 32(6): 678-681.

参考文献

[1] Stritar J, Stavber L, Ficko M,et al.Detection of Del/Dup inside SHOX/PAR1 region in children and young adults with idiopathic short stature[J].Genes, 2021, 12(10):1546.
[2] 费丹宏.重组人生长激素治疗特发性矮小症的疗效及对患儿生长发育的影响[J].中国妇幼保健,2021,36(6):1311-1314.
Fei DH. Efficacy of recombinant human growth hormone in the treatment of idiopathic short stature and its effects on the growth and development of young children[J].Maternal and Child Health Care in China, 2021,36(6): 1311-1314.(in Chinese)
[3] 邓茜,陈雨青,王娟娟,等.特发性矮小症患儿治疗前后血清IGF-1、IGFBP-3、25-(OH)D、皮质醇水平变化及其与体格发育和骨龄的相关性分析[J].现代生物医学进展,2022,22(18):3524-3527,3595.
Deng Q, Chen YQ, Wang JJ, et al. Changes in serum IGF-1, IGFBP-3,25-(OH) D, cortisol levels and their correlation with physical development and bone age before and after treatment of children with idiopathic short stature[J].Advances in Modern Biomedicine, 2022,22(18): 3524-3527,3595.(in Chinese)
[4] 钱昊,俞艳梅,吴琪,等.矮小症儿童骨密度与血清维生素D IGF-1 IGFBP-3的相关性分析[J].河北医学,2022,28(7):1148-1152.
Qian H, Yu YM, Wu Q, et al. Correlation analysis of bone mineral density and serum vitamin D IGF-1 IGFBP-3 inchildren with short stature[J].Hebei Medical Science Center, 2022,28(7): 1148-1152.(in Chinese)
[5] 鲁燕飞,金平.矮小症患儿血清胰岛素样生长因子-1 25-(OH)D-羟维生素D水平及临床特征分析[J].中国妇幼保健,2021,36(11): 2580-2582.
Lu YF, Jin P.Analysis of serum insulin-like growth factor-1 25-(OH)D-hydroxyvitamin D level and clinical characteristics in children with short stature[J]. Maternal and Child Health in China, 2021,36(11): 2580-2582.(in Chinese)
[6] 胡亚美.诸福棠实用儿科学[M].北京:人民卫生出版社, 2002:1199-1200.
[7] Jensen KY, Aagaard P, Schrder HD,et al.High-intensity strength training in patients with idiopathic inflammatory myopathies:A randomised controlled trial protocol[J].BMJ Open, 2021, 11(6):e043793.
[8] Buchanan I, Lee NJ, Kerolus M,et al.The "Touched Vertebra(TV)" provides a reliable method for lowest instrumented vertebra(LIV) selection in adult idiopathic scoliosis(AdIS)[J].Spine Journal, 2021, 21(9):S28.
[9] 张蔷,刘丽君,李金英,等.来曲唑改善青春期特发性矮小症男童身高的疗效观察[J].实用医学杂志, 2021, 37(3):369-373.
Zhang Q, Liu LJ, Li JY, et al. Efficacy of letrozole on improving height in boys with idiopathic short stature in adolescence[J]. Journal of Practical Medicine, 2021,37(3): 369-373.(in Chinese)
[10] 马梦瑾,罗臻臻,李志洁. 重组人生长激素治疗特发性矮小症对患儿血清p21 waf/cip1、瘦素水平及生长情况的影响[J]. 中华生物医学工程杂志,2021,27(3):311-314.
Ma MJ, Luo ZZ, Li ZJ. Effect of recombinant human growth hormone treatment for idiopathic short stature on serum p21 waf/cip 1, leptin levels and growth in children[J]. Chin J Biological Eng, 2021,27(3): 311-314.(in Chinese)
[11] 季芳璐.矮小症患儿生长激素治疗后身高获益的临床研究[J].重庆医学, 2021, 50(Suppl 1):3.
Ji FL. Clinical study of height benefit after growth hormone therapy in children with short stature[J]. Chongqing Medical, 2021,50(Suppl 1): 3.(in Chinese)
[12] 郭林梅,戴永利,赵晓云,等.中国西部高海拔地区特发性矮小症男性患儿应用不同剂量rhGH治疗方案的临床疗效[J].兰州大学学报:医学版,2022,48(6):35-38.
Guo LM, Dai YL, Zhao XY, et al. Clinical efficacy of different doses of rhGH in male children with idiopathic short stature at high altitude in western China[J]. Journal of Lanzhou University: Medical Edition, 2022,48(6): 35-38.(in Chinese)
[13] 蒋芬,陈伟楚,何春霞.特发性矮小症患儿血清IGF-1、皮质醇、hGH变化及其临床意义[J].中国妇幼健康研究,2021,32(2):225-228.
Jiang F, Chen WC, He CX. Changes in serum IGF-1, cortisol, and hGH and their clinical significance in children with idiopathic short stature[J]. China Maternal and Child Health Research, 2021,32(2): 225-228.(in Chinese)
[14] 何凤,王城,赵丹,等.GHIGF遗传变异与特发性矮小症的发病及甲状腺结合球蛋白缺乏的关系[J].临床和实验医学杂志,2022,21(21):2323-2326.
He F, W C, Zhao D, et al. Association between GHI GF genetic variation and the onset of idiopathic short stature and thyroid-binding globulin deficiency[J]. Journal of Clinical and Experimental Medicine, 2022,21(21): 2323-2326.(in Chinese)
[15] 黄占克,刘怡闻,李维丽,等. 赖氨酸磷酸氢钙颗粒联合重组人生长激素治疗儿童特发性矮小症的临床研究[J]. 现代药物与临床,2021,36(6):1203-1206.
Huang ZK, Liu YW, Li WL, et al. Clinical study of lysine calcium hydrogen phosphate granules combined with recombinant human growth hormone for idiopathic short stature in children[J]. Modern Medicine and Clinical, 2021,36(6): 1203-1206.(in Chinese)